You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
PLGA encapsulated polyphenols to ameliorate IBD.
SBC: THERAPYX, INC. Topic: RAbstract Green tea has received increased attention recentlydue to several epidemiological and clinical studies showing a positive relationship between consumption and disease preventionBenefits include reduced risk of cardiovascular diseasese gmyocardial infarctionhypertensionatherosclerosisneurodegenerative diseasese gParkinson s and Alzheimer s diseaseand certain cancerse ggastricbreast and cer ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Left atrial appendage closure device with catheter-based delivery for patients with non-valvular atrial fibrillation
SBC: Cor Habere Corp. Topic: RIn the USthere aremillion patients with nonvalvular atrial fibrillationNVAFwhich is expected to increase tomillion byThe treatment of NVAF is estimated to cost $billionincluding $billionfor hospitalizations aloneThe most significant morbidity and mortality associated with NVAF is embolic strokewithof thrombus originating from the left atrial appendageLAAAnticoagulation is the preferred treatment f ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a sutureless LVAD outflow graft anastomotic quick-connect system
SBC: Myocardial Assist Systems & Technology LLC Topic: NHLBIHeart failureHFis the leading cause of death in the United Statesaffecting nearly six million people at a cost over $billionClinically approved mechanical circulatory supportMCStherapysuch as left ventricular assist devicesLVADscontinue to improve as a viable treatment option for patients with advanced heart failure as evidenced by overimplants over the past five yearsHoweverMCS device therapy can ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Robust Predictor of Colon Cancer Risk
SBC: Morgan and Mendel Genomics, Inc. Topic: 102Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
DIAGNOSTIC TEST FOR METASTATIC KIDNEY CANCER
SBC: LaGrange Scientific, LLC Topic: 102ABSTRACTThe goal of this Phase I SBIR is to address the absence of measureable and targeted metabolite biomarkers in clear cell renal cell carcinomaccRCCtissues that can predict disease metastasisAn estimatedAmericans were diagnosed with kidney cancer inand approximatelydied as a result of ccRCCprimarily due to metastasis of the cancerUltimatelywe seek to identify those patients with more aggressi ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an a MC1R selective companion diagnostic imaging probe
SBC: MODULATION THERAPEUTICS, INC. Topic: 102The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
SBC: NAPROGENIX, INC. Topic: NINDSAbstract Alpha synucleinASYNis believed to play an important role in the pathology of several neurodegenerative conditionsincluding some forms of Parkinsonandapos s diseaseDementia with Lewy Bodiesand Multiple Systems AtrophyThe most recent hypothesis is that the ASYN proteinsparticularly genetic variants such as AT that are prone to misfoldingare cleaved by the lysosomal enzymeasparagine endopept ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive Seizure Screening in Preclinical Models of Epilepsy
SBC: SIGNAL SOLUTIONS LLC Topic: 100Noninvasive Seizure Screening in Preclinical Models of Epilepsy There is an urgent need for research into treatment options for epilepsy and other seizure disordersAnimal models are increasingly used to understand disease mechanisms and to screen promising therapeutic approachesAnimal epilepsy model use typically requires expensive and labor intensive experimentationwith invasive EEG measurements ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Exploiting activation-induced cell death as a means of inducing tolerance to kidney allografts
SBC: FasCure Therapeutics LLC Topic: NIAIDPROJECT SUMMARY Kidney transplantation is the preferred treatment for patients with end stage renal diseaseHoweverstandard immunosuppression to control rejection is the major limitationAlthough standard immunosuppression has gradually been improved for better efficacy and safetyit still carries a great risk for adverse effects ranging from malignancies and infections to cardiovascular complication ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a Percutaneous Pulmonary Artery Drainage Device to Unload LV During VA ECMO Support for Severe Cardiogenic Shock
SBC: W-Z BIOTECH LLC Topic: NHLBICardiogenic shockCSis a serious clinical condition of reduced cardiac outputCOwith end organ hypoperfusionIn severe CSend organ hypoperfusion leads to multi organ failureand elevated left ventricleLVpreload increases LV wall stressexacerbating myocardial injuryVenoarterial extracorporeal membrane oxygenationVA ECMOhas been increasingly used to support severe CS patients due to its high efficiencyc ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health